Serum Glucose and Fructosamine in Relation to Risk of Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Wulaningsih, Wahyu ^a   Holmberg, Lars ^a,b,c   Garmo, Hans ^a,c   Zethelius, Björn ^d,e   Wigertz, Annette ^c   Carroll, Paul ^f   Lambe, Mats ^c,g   Hammar, Niklas ^g,h   Walldius, Göran ^g   Jungner, Ingmar ^g   Van Hemelrijck, Mieke ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Regional Cancer Centre   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g KAROLINSKA INSTITUTE   (Sweden)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLUCOSE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; FEMALE; FRUCTOSAMINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 84872860354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054944     Document Type: Article

References (42)

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, (2005) Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366: 1784-1793.
2. Ford ES, Zhao G, Li C, (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55: 1310-1317.
3. Ogunleye AA, Ogston SA, Morris AD, Evans JM, (2009) A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 101: 1199-1201.
4. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, et al. (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49: 945-952.
5. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-221.
6. Stopper H, Schinzel R, Sebekova K, Heidland A, (2003) Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 190: 151-156.
7. Rojas A, Gonzalez I, Morales E, Perez-Castro R, Romero J, et al. (2011) Diabetes and cancer: Looking at the multiligand/RAGE axis. World J Diabetes 2: 108-113.
8. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, et al. (2010) Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70: 741-751.
9. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, et al. (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293: 194-202.
10. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, et al. (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6: e1000201.
11. De Michele G, Correale M, De Michele O, Guerra V, Mazzarelli R, et al. (2008) Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects. Immunopharmacol Immunotoxicol 30: 925-936.
12. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, et al. (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125: 2704-2710.
13. Kabat GC, Kim MY, Strickler HD, Shikany JM, Lane D, et al. (2012) A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer 106: 227-232.
14. True MW, (2009) Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol 3: 743-747.
15. Platek M, Krogh V, Micheli A, Browne R, Meneghini E, et al. (2005) Serum fructosamine and subsequent breast cancer risk: a nested case-control study in the ORDET prospective cohort study. Cancer Epidemiol Biomarkers Prev 14: 271-274.
16. Misciagna G, De Michele G, Guerra V, Cisternino AM, Di Leo A, et al. (2004) Serum fructosamine and colorectal adenomas. Eur J Epidemiol 19: 425-432.
17. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G, (2009) Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 265: 275-287.
18. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G, (2009) Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 266: 558-570.
19. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, et al. (1998) Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 44: 1641-1649.
20. Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, et al. (2006) Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 97: 943-946.
21. Lamb E, Mainwaring-Burton R, Dawnay A, (1991) Effect of protein concentration on the formation of glycated albumin and fructosamine. Clin Chem 37: 2138-2139.
22. (2008) Central Bureau for Statistics. Statistics Sweden. Stockholm, Sweden: Central Bureau for Statistics.
23. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, et al. (2008) Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 32: 304-314.
24. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, et al. (2009) RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7: 17.
25. Stumvoll M, Goldstein BJ, van Haeften TW, (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
26. Pollak M, (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
27. Gallagher EJ, LeRoith D, (2011) Minireview: IGF, Insulin, and Cancer. Endocrinology 152: 2546-2551.
28. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353.
29. Brewer N, Wright CS, Travier N, Cunningham CW, Hornell J, et al. (2008) A New Zealand linkage study examining the associations between A1C concentration and mortality. Diabetes Care 31: 1144-1149.
30. Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, Marz W, (2011) Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care 34: 1355-1361.
31. Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, et al. (2011) Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res 71: 3582-3589.
32. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, et al. (2011) Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 20: 1430-1438.
33. Cohen RM, Holmes YR, Chenier TC, Joiner CH, (2003) Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 26: 163-167.
34. Baker JR, O'Connor JP, Metcalf PA, Lawson MR, Johnson RN, (1983) Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. Br Med J (Clin Res Ed) 287: 863-867.
35. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 317: 371-375.
36. Fisher LD, Lin DY, (1999) Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20: 145-157.
37. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350: 1047-1059.
38. Walker K, Bratton DJ, Frost C, (2011) Premenopausal endogenous oestrogen levels and breast cancer risk: a meta-analysis. Br J Cancer 105: 1451-1457.
39. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, et al. (2011) Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 22: 1163-1171.
40. Kasper JS, Giovannucci E, (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056-2062.
41. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, et al. (2001) Cigarette smoking and glycaemia: the EPIC-Norfolk Study. European Prospective Investigation into Cancer. Int J Epidemiol 30: 547-554.
42. Van Hemelrijck M (2010) Thesis for doctoral degree (PhD). Metabolic Syndrome and Prostate Cancer: Biomarkers and Treatment Side-effects. London: King's College London.